New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

Data ReadoutpositiveTECVAYLIDARZALEX FASPROPositive

AI Analysis

Summary

Model-based analysis of TECVAYLI plus DARZALEX FASPRO combination therapy shows ~87% of early-line relapsed/refractory multiple myeloma patients achieved mortality risk comparable to general population, with 90% reduction in myeloma-related mortality risk.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Model-based analysis shows ~87% of patients treated with TECVAYLI plus DARZALEX FASPRO as early as second line were estimated to have comparable mortality risk to general population; 90% reduction in multiple myeloma-related mortality risk

Importance:6/10

Sentiment:

0.85

multiple myelomarelapsed/refractorysurvival datacombination therapymodel-based analysis

Read the original article

Published by PR Newswire Pharma on September 23, 2026 1:46 PM

Read Original